Home > Press > Nanobac Pharmaceuticals Announces Continuation of Space Act Agreement with NASA: NASA to Study Characterization of the Physical and Chemical Propertie
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or the "Company") is pleased to announce the signing of a Space Act Agreement with NASA's Johnson Space Center (JSC), Houston Texas, to collaborate on research on Calcifying Nanoparticles (CNP) and its nature and role in pathological calcification, including the detection and treatment of the pathogen. Since Astronauts may be more prone to an increased rate of pathological calcification while in a zero gravity environment, the collaboration will bring a new approach to NASA's need to better understand the effects of long-term space travel on humans.
Nanobac Pharmaceuticals Announces Continuation of Space Act Agreement with NASA: NASA to Study Characterization of the Physical and Chemical Propertie
TAMPA, FL | Posted on September 18th, 2007
NANOBAC and NASA are interested in pathological calcium phosphate particles found in diseases such as kidney stones, prostatitis, and arthritis, which are all conditions that accelerate in humans in a zero gravity environment. This collaboration would provide NASA the opportunity to utilize NANOBAC's diagnostic and treatment experience in this field in support of NASA's exploration goals related to understanding the effects of long-term space travel on humans and offer Nanobac the opportunity to further develop its methods and utilize NASA instrumentation to further characterize the CNPs.
Part of the instrumentation to be used is the Focused Ion Beam (FIB) in order to mill CNP samples for use in Scanning and Transmission Electron Microscopy (SEM, TEM, STEM) analyses to characterize internal CNP mineralogy. Additionally, Laser Microprobe, Organic Mass-Spectrometric analyses and Nano-SIMS elemental and isotopic analyses will be performed to characterize the organic content of the CNPs.
"We are pleased to be able to extend our Director of Science time at NASA for these important projects," commented Dr. Benedict Maniscalco, Nanobac's Co-Chair and Chief Medical Officer. "We appreciate the opportunity to work with some of the country's most talented scientists."
Nanobac's Director of Science Neva Ciftcioglu added: "The continuation of our collaborative research with NASA will give us an opportunity to stay with exceptionally experienced diverse scientific members helping us to complete the biological definition of the unique agent: calcifying nanoparticles."
About Nanobac Pharmaceuticals Inc.
Our objective is to develop methods to treat Calcifying Nanoparticles (CNPs), and by so doing find more effective approaches to the diseases associated with them.
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
For more information, please click here
Nanobac Pharmaceuticals, Tampa
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Novel nanoparticle therapy promotes wound healing March 27th, 2015
Graphene reduces wear of alumina ceramic March 26th, 2015
Application of Graphene Oxide in Body Implants in Iran March 26th, 2015
Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015
A first glimpse inside a macroscopic quantum state March 28th, 2015
DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015
Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015
Using magnetic fields to understand high-temperature superconductivity: Los Alamos explores experimental path to potential 'next theory of superconductivity' March 27th, 2015
Iranian Researchers Present Model to Determine Dynamic Behavior of Nanostructures March 24th, 2015
Engineers create chameleon-like artificial 'skin' that shifts color on demand March 12th, 2015
Anousheh Ansari Wins the National Space Society's Space Pioneer Award for "Service to the Space Community" March 5th, 2015
Launch of the Alliance for Space Development March 1st, 2015